OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid ...
OS Therapies Incorporated (OSTX) is a clinical-stage biopharmaceutical company headquartered in Grasonville, Maryland, and listed on the NYSE Arca. Founded in 2018, the company is dedicated to addressing the unmet medical needs of patients with osteosarcoma and other solid tumors, an area where no new treatments have emerged in over 30 years. The company’s pipeline features two proprietary technologies: OST-HER2, an off-the-shelf immunotherapy aimed at treating osteosarcoma, and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate platform that employs pH-sensitive silicone linkers for targeted drug delivery. These technologies are designed to activate the immune system and improve therapeutic outcomes. As a small company with only 4 full-time employees, OS Therapies operates efficiently, leveraging the experience of its leadership team, including CEO Paul Romness, who has over 25 years in the biopharmaceutical industry with experience at Johnson & Johnson and Amgen. Financially, the company is in its early stage, reporting no revenue, negative earnings, and negative cash flows from operations, which is typical for clinical-stage biotech firms. The company’s market capitalization is approximately $72.9 million, with a stock price around $1.60. Despite the challenging financial metrics, including negative book value and negative return on assets, the company is actively investing in research and development to advance its pipeline. The company's focus on pediatric cancer and solid tumors, combined with its innovative technology, positions it as a potential player in the oncology space, though significant risks remain given the early stage of development and limited resources.
